Blood sugar tracker may extend life in brain cancer patients

NCT ID NCT07091864

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests whether a continuous glucose monitor (CGM) can help people with glioblastoma, a severe brain cancer, manage their blood sugar levels and potentially live longer. High blood sugar during treatment is linked to worse outcomes, often caused by steroids. The CGM device tracks glucose in real time, allowing for quicker treatment. The trial will enroll 116 newly diagnosed patients to see if this approach improves survival at 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE WHO GRADE 4 GLIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Arizona
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States

Contact Email: •••••@•••••
Mayo Clinic in Florida
NOT_YET_RECRUITING

Jacksonville, Florida, 32224, United States

Contact Email: •••••@•••••
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.